IPSC Stock Analysis: Buy, Sell, or Hold?
IPSC - Century Therapeutics, Inc. Common Stock
$2.30
0.05 (2.22%)
▲
5d:
+8.49%
30d:
-3.36%
90d:
-5.35%
BUY
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 20, 2026
0d
Get Alerted When IPSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IPSC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IPSC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IPSC is currently trading at $2.30, which is considered slightly high relative to its 30-day fair value range of $2.16 to $2.34.
Technical Outlook: Technically, IPSC is showing sideways momentum. Immediate support is located at $1.98, while resistance sits at $2.52.
Market Sentiment: IPSC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $4.75 (+106.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IPSC is showing sideways momentum. Immediate support is located at $1.98, while resistance sits at $2.52.
Market Sentiment: IPSC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $4.75 (+106.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.16 -
$2.34
Company Quality Score
57/100
(HOLD)
Options IV Signal
100th percentile
(ELEVATED)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 106.5% below Wall St target ($4.75)
Trading Range Analysis
30-Day Trading Range
$2.16 -
$2.34
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.51
(22.2%)
Support & Resistance Levels
Support Level
$1.98
Resistance Level
$2.53
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.03
Wall Street Target
$4.75
(+106.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 15, 2026 11:27 PM ET
Data refreshes hourly during market hours. Next update: 12:27 AM
Data refreshes hourly during market hours. Next update: 12:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPSC showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Gregory Russotti
SELL
10076 shares
2026-03-12
Douglas Carr
SELL
7043 shares
2026-03-12
Gregory Russotti
SELL
479 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 61 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$187 | 58 HOLD |
|
VYGR
Voyager Therapeutics Inc |
STRONG BUY
12 analysts |
$15 | 56 HOLD |
